

Access to medicines policy

Access to medicines policy

Allergy is the most common chronic disease in the world. Allergic reactions to pollen, food and animals impact millions of peoples' work and everyday life and well-being. Globally, 500 million people are affected by allergic rhinitis, and 10-20% of these have symptoms, which are not well controlled. People who experience insufficient effect from symptomatic medication can benefit from allergy immunotherapy (AIT). ALK-Abelló (ALK) offers products, services and resources covering a wide range of allergies. The company also has products in related areas, including diagnosis and emergency treatment. The journey towards successfully managing symptoms is often long and cumbersome for people with allergies. Many of them choose to self-medicate through over-the-counter medication. However, this prolonged road to managing allergies has a profound impact on people's quality of life and has significant impact on healthcare systems and global economic development through lost productivity¹ and lost workdays.

Statement of policy

The purpose of this policy is to set forth the respective principles related to our position on access to medicines and provide information and guidance on management of the access to medicines strategy for the entire ALK Group. ALK's access to medicines policy applies to all employees of ALK, including all directors, officers, managers, employees and temporary staff worldwide (collectively referred to as "ALK employees"), when dealing on behalf of ALK.

Access to allergy care

The purpose of ALK's access to medicines strategy is to enable access to allergy care. Our products and services are relevant to

populations across the entire globe, and our goal is to democratise and disseminate these to many more, earlier in their allergy journey.

We apply two principles to enable access to allergy care:

- Our primary focus is people with allergies and their need for a correct diagnosis and treatment
- Assisting healthcare systems and healthcare professionals (HCPs) is a precondition for providing efficient allergy care. Without a healthcare infrastructure, people with allergies cannot benefit from our allergy solutions

In order to fulfil this purpose, we build on decades of research and development, and apply state-of-the-art pharmaceutical standards to deliver products and services to millions in need. However, millions more lack access to modern medical care for their allergies and related asthma.

Our ambition is to ensure:

Access to allergy care through earlier introduction of allergy solutions in the patient journey and better treatment outcomes.

ALK achieves this by accommodating patients' needs for allergy diagnosis and treatment, as described in the principles outlined above, including through partnerships in emerging markets. ALK aims to contribute to overcoming barriers to access by continuing efforts in driving solid, evidence-based research and development of state-of-the-art pharmaceutical products, including maintaining their applicability across genders, ages and ethnicity.

ALK plays a vital role in strengthening healthcare systems to ensure safe, effective and quality medicines for people with allergies. Through our expertise and capacity, we help strengthen local health systems through training and educational activities for HCPs in alignment with local needs, either ourselves or

¹ Jinett K. The Center for Workforce Health and Performance; 2016

Access to medicines policy

through appropriate partners to mitigate any potential conflicts of interest. New business models and partnerships with healthcare systems and HCPs are explored to enable accessibility in areas and geographies, both developed and emerging, to an increasing number of countries and patients across the globe. ALK's responsibility also extends to awareness raising activities, training and education efforts of both HCPs and people challenged by allergies.

Strategic-level SDG-impact achieved through our access to allergy care approach:

- SDG 3 is a primary focus for ALK and is operationalised in programmes of democratisation and dissemination of allergy medicine. ALK enables access to safe, effective, quality and affordable essential medicines and vaccines, and thus contributes positively to SDG target 3.8. ALK contributes to healthy lives and promotes well-being for people with allergies at all ages.

- SDG 9 supports access to medicines efforts through research-based development and digitised information about allergies ensuring quality of life for all groups. ALK enables increased accessibility to allergy immunotherapy, through research and development activities and technological development, and contributes to the realisation of SDG target 9.5.

Measuring impact

ALK has integrated two long-term strategic goals, as well as short-term milestones into our overall business operations that enable access to allergy care and support SDGs 3 and 9:

2030 Goals	Milestones
Enable accessibility to ALK allergy diagnosis, AIT and/or adrenaline products by increasing the number of patients annually by at least 100.000	2025: Children and/or adolescent indication added to current indication in 10+ countries
	2023: Make ALK allergy diagnosis, AIT and/or adrenaline products accessible to at least 300.000 additional patients
	2025: Introduce tablet-based AIT in 5+ new countries
Educate 200.000 HCPs and establish partnerships to train 50.000 HCPs in allergy treatment and AIT	2022: Educate 20.000 HCPs in allergy treatment and AIT
	2022: Establish partnerships to train 4.000 HCPs in allergy treatment and AIT

Access to medicines policy

Access to allergy care governance setup

The oversight, accountability and responsibility for the strategy and purpose of the access to allergy care programme rests with ALK's Board of Directors, who have delegated this responsibility to the Board of Management. Access to allergy care targets are integrated into the short- and long-term incentive programmes at the executive level.

Relevant business units across ALK are responsible for the daily management of the access to allergy care strategy and the operational-level targets, including monitoring of development, risk identification and management, integration into decision-making and processes and internal reporting to the ALK Sustainability team. The team coordinates and supports implementation and daily management of the strategy. The identification, planning and financing of connected activities are conducted by the ALK Sustainability Committee to support the fundamental human right of accessibility to healthcare for all as stated in the Universal Declaration of Human Rights

The Sustainability Committee consists of members of the extended Board of Management and representatives from relevant business units across ALK. The ALK Sustainability team is responsible for the daily management of the access to allergy care strategy and reporting internally to the ALK Board of Management and Board of Directors.

Responsible business practices

ALK is committed to enabling access to more people with allergies, while ensuring that ALK continues to be a sustainable business. We practice business responsibly by adhering to all relevant laws, industry codes and guidelines², including in:

- Interactions with HCPs, patient organisations and the general public
- Conducting clinical trials and post-marketing activities
- Combatting corruption and anti-competitive behaviour (IP and non-IP-related)
- Promotion and marketing of treatment and services

Health systems are supported through partnerships, including local stakeholders and in line with local needs.

Communication and reporting

ALK is inspired by internationally recognised standards such as the Access to Medicine Index to determine scope and materiality of activities implemented. Our work with sustainability centres on an ambition to contribute to the 2030 Agenda for Sustainable Development and is monitored on the basis of relevant indicators.

ALK is committed to reporting about progress in a timely, accurate, balanced and clear manner both internally and externally to other stakeholders through our website, annual sustainability report as well as other channels. ALK will report on progress in relation to KPIs, risks, mitigating tactics and achieved results in connection with the development of the annual sustainability report.

ALK's access to medicines policy and strategy is reviewed continually by the Board of Management to ensure alignment with the overall strategy of the ALK group. The current version of the policy was considered and approved by the Board of Management on 1 February 2021.

² ALK adheres to the European Federation of Pharmaceutical Industries and Associations' (EFPIA's), the International Federation of Pharmaceutical Manufacturers & Associations' (IFPMA's) Codes of Practice, as well as relevant codes and guidelines by the Pharmaceutical Research and Manufacturers of America (PhRMA).